TNFRSF18 and ovarian cancer: We first assessed the antitumor effects of either single or combined anti-PD-1/GITRmAb in murine ID8 ovarian cancer, a highly clinical relevant model with ascitesformation and metastases in peritoneal cavity (Figure 1A).Group of C57BL/6 mice were i.p. transplanted with 5 × 106 ID8 cellson day 1 and then were treated with i.p. injection of control, anti-PD-1, anti-GITRor anti-PD-1/GITR mAb on day 8, 11 and 15.